|
Phenotype
|
Control (%)
|
CBD (%)
|
T
test
|
|---|
|
Resting splenocytes
| | | |
|
CD4+
|
20.0 ± 2.7
|
20.7 ± 2.2
|
ns
|
|
CD4+CD69+
|
6.9 ± 1.2
|
8.7 ± 1.9
|
ns
|
|
CD4+LAG3+
|
0.5 ± 0.3
|
0.4 ± 0.4
|
ns
|
|
CD19+
|
59.4 ± 2.0
|
59.4 ± 2.1
|
ns
|
|
CD19+CD69+
|
13.6 ± 3.4
|
17.4 ± 3.4
|
ns
|
|
CD19+CD25+
|
2.5 ± 0.2
|
3.1 ± 0.2
|
ns
|
|
Resting TMOG cells
| | | |
|
CD69+
|
0.9 ± 0.3
|
1.0 ± 0.2
|
ns
|
|
LAG3+
|
0.7 ± 0.2
|
0.5 ± 0.1
|
ns
|
- Freshly isolated mouse splenocytes (including accessory CD4+ T cells and CD19+ B cells) or resting TMOG cells were maintained separately for 18 h in maintenance medium without MOG35-55 and in the presence or absence of CBD at 5 μM. CD69, LAG3 and CD25 surface expression was analyzed using flow cytometry (n = 3). Data are expressed as percentage ± SEM defined as the percent of cells expressing relevant antigen within an appropriate parent population.
- ns, not significant.
